KRBP - Kiromic BioPharma, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Houston,
United States
Type: Equity
KRBP price evolution
KRBP
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2.7 | $2.05 | $0.65 | $0.43 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $4.71 | $3.52 | $1.69 | $2.14 |
| Long term investments | ||||
| Property, plant & equipment | $8.9 | $9.57 | $10.25 | $10.85 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $8.92 | $9.59 | $10.28 | $10.88 |
| Total investments | ||||
| Total assets | $13.64 | $13.11 | $11.97 | $13.02 |
| Current liabilities | ||||
| Accounts payable | $6.62 | $8.15 | $7.31 | $6.49 |
| Deferred revenue | ||||
| Short long term debt | $8.87 | $10.58 | $4.95 | $0.55 |
| Total current liabilities | $18.7 | $19.86 | $13.28 | $11.11 |
| Long term debt | $1.23 | $1.39 | $4.46 | $1.63 |
| Total noncurrent liabilities | $1.23 | $1.39 | $4.46 | $1.63 |
| Total debt | $10.1 | $11.97 | $9.41 | $2.17 |
| Total liabilities | $19.93 | $21.25 | $17.74 | $12.74 |
| Shareholders' equity | ||||
| Retained earnings | -$114.01 | -$107.25 | -$101.95 | -$94.88 |
| Other shareholder equity | ||||
| Total shareholder equity | -$6.29 | -$8.14 | -$5.77 | $0.28 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $0.65 | $25.35 | $10.15 | $1.93 |
| Short term investments | ||||
| Net receivables | $0.02 | |||
| Inventory | $0.02 | |||
| Total current assets | $1.69 | $27.07 | $10.74 | $2.04 |
| Long term investments | ||||
| Property, plant & equipment | $10.25 | $3.63 | $2.07 | $0.59 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $10.28 | $3.66 | $2.09 | $0.61 |
| Total investments | ||||
| Total assets | $11.97 | $30.73 | $12.83 | $2.65 |
| Current liabilities | ||||
| Accounts payable | $7.31 | $2.21 | $0.67 | $0.45 |
| Deferred revenue | ||||
| Short long term debt | $4.95 | $0.45 | $0.47 | |
| Total current liabilities | $13.28 | $3.41 | $1.47 | $0.67 |
| Long term debt | $4.46 | |||
| Total noncurrent liabilities | $4.46 | |||
| Total debt | $9.41 | $0.45 | $0.47 | |
| Total liabilities | $17.74 | $3.41 | $1.47 | $0.67 |
| Shareholders' equity | ||||
| Retained earnings | -$101.95 | -$67.22 | -$41.63 | -$22.43 |
| Other shareholder equity | ||||
| Total shareholder equity | -$5.77 | $27.32 | $11.36 | $1.98 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $1.97 | $2.08 | $3.33 | $3.78 |
| Selling, general & administrative | $2.33 | $2.7 | $3.59 | $4.61 |
| Total operating expenses | $4.29 | $4.78 | $6.92 | $8.4 |
| Operating income | -$4.29 | -$4.78 | -$6.92 | -$8.4 |
| Income from continuing operations | ||||
| EBIT | -$6.43 | -$4.86 | -$6.91 | -$11.86 |
| Income tax expense | ||||
| Interest expense | $0.34 | $0.44 | $0.16 | $0 |
| Net income | ||||
| Net income | -$6.76 | -$5.3 | -$7.07 | -$11.86 |
| Income (for common shares) | -$6.76 | -$5.3 | -$7.07 | -$11.86 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $13.92 | $11.37 | $5.05 | $1.2 |
| Selling, general & administrative | $17.19 | $13.94 | $14.14 | $2.5 |
| Total operating expenses | $31.11 | $25.74 | $19.2 | $3.68 |
| Operating income | -$31.11 | -$25.74 | -$19.2 | -$3.68 |
| Income from continuing operations | ||||
| EBIT | -$34.56 | -$25.58 | -$19.2 | -$3.71 |
| Income tax expense | ||||
| Interest expense | $0.17 | $0.01 | $0 | $0.02 |
| Net income | ||||
| Net income | -$34.73 | -$25.59 | -$19.2 | -$3.73 |
| Income (for common shares) | -$34.73 | -$25.59 | -$19.2 | -$3.73 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Net income | -$6.76 | -$5.3 | -$7.07 | -$11.86 |
| Operating activities | ||||
| Depreciation | $0.69 | $0.69 | $0.95 | $0.54 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.04 | $0.02 | $0.61 | $0.36 |
| Total cash flows from operations | -$6.46 | -$4.13 | -$4.1 | -$6.1 |
| Investing activities | ||||
| Capital expenditures | -$0.04 | $0.13 | ||
| Investments | ||||
| Total cash flows from investing | -$0.04 | $0.13 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.58 | |||
| Net borrowings | $6.53 | $5.54 | $4.36 | -$0.11 |
| Total cash flows from financing | $7.11 | $5.54 | $4.36 | -$0.11 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $0.65 | $1.41 | $0.21 | -$6.08 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$34.73 | -$25.59 | -$19.2 | -$3.73 |
| Operating activities | ||||
| Depreciation | $2.07 | $0.47 | $0.2 | $0.09 |
| Business acquisitions & disposals | $0.08 | |||
| Stock-based compensation | $1.24 | $3.76 | $13.25 | $0.52 |
| Total cash flows from operations | -$23.75 | -$20.32 | -$6.13 | -$2.91 |
| Investing activities | ||||
| Capital expenditures | -$4.87 | -$1.89 | -$1.46 | -$0.3 |
| Investments | ||||
| Total cash flows from investing | -$4.87 | -$1.81 | -$1.46 | -$0.3 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $40.13 | $15 | $0.01 | |
| Net borrowings | $3.9 | $0.09 | $0.47 | $0.25 |
| Total cash flows from financing | $3.9 | $37.34 | $15.81 | $4.76 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$24.71 | $15.2 | $8.22 | $1.54 |
News
Fundamentals
| Market cap | $3.20M |
|---|---|
| Enterprise value | $10.60M |
| Shares outstanding | 1.18M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$27.18M |
| EBIT | -$30.05M |
| Net Income | -$30.99M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.10 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | -0.39 |
| EV/EBIT | -0.35 |
| P/S ratio | N/A |
| P/B ratio | -0.51 |
| Book/Share | -5.33 |
| Cash/Share | 2.29 |
| EPS | -$26.27 |
|---|---|
| ROA | -239.64% |
| ROE | 622.17% |
| Debt/Equity | -3.07 |
|---|---|
| Net debt/EBITDA | -0.63 |
| Current ratio | 0.25 |
| Quick ratio | 0.25 |